Business Wire

IDEMIA Announces a Change in Its Top Management Team, with a View to Building on Its Global Leadership in Augmented Identity

Jaa

Didier LAMOUCHE, CEO of IDEMIA, today announced the appointment of two new members of IDEMIA’s Executive Committee. Philippe BARREAU (formerly MD of SICPA SA, a Swiss company providing secured identification and authentication solutions and services) will head up both the Citizen Identity and Public Security business units as Group Executive Vice-President, while Ed CASEY (former Chief Operating Officer of Serco, a UK-based global provider of public services in various areas, including citizen services) is appointed CEO of the Noram Identity & Security business unit.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180110005554/en/

Pierre BARRIAL (who was running the Mobile Operators business) is appointed Group Executive Vice-President of the Financial Institutions business unit. He has a successful record of accomplishment in managing organizations in challenging technology environments across multiple companies.

Fabien JAUTARD, who was previously managing the Mobile Operators activity in the Asia Pacific Region, replaces Pierre BARRIAL as Executive Vice-President of the Mobile Operators business unit. Fabien JAUTARD will also join IDEMIA’s Executive Committee.

IDEMIA currently operates in 180 countries, where it employs 14,000 people. In an ever more competitive market, the firm has also decided to strengthen its regional structure and has appointed new Presidents in charge of two regions. Eric DUFOREST, previously in charge of driving the global Financial Institutions activity, will now manage the Asia-Pacific Region. His recent success heading IDEMIA’s Financial Institutions business for five years makes Eric DUFOREST the ideal candidate to lead the group growth effort in the APAC Region. Marcello BELLINI, in charge of the Financial Institutions operations in Latin America, will also take the role as of now of President of the Latin America Region.

Philippe D'ANDREA is appointed European region President on top of his duties as Global Operations manager. His role will be to roll out and communicate the group strategy throughout the Region.

All the above appointments take effect immediately.

The result of the coming together, in May 2017, of OT (Oberthur Technologies) and Safran Identity & Security (Morpho), the new IDEMIA identity was unveiled on 28th September 2017. It is the global leader in Augmented Identity for an increasingly digital world, with a view to provide citizens and consumers with end-to-end full-secured solutions, when they interact, pay, connect, travel and vote.

IDEMIA will also continue to invest in R&D to develop high-tech future game-changing innovations and solutions amounting to €1bn over five years, by tapping into the strengths and know-how of the two companies that formed IDEMIA, while serving both public and private sector customers.

Didier LAMOUCHE, CEO of IDEMIA group, declared: “The strategic intent behind the creation of IDEMIA is to offer to the world state-of-the-art security solutions together with biometric-based convenience. The new management team is composed of talented and skilled leaders, coming from various horizons, who will be capable to deliver upon this vision and address and anticipate our clients’ needs worldwide.”

Additional Information about Philippe Barreau

Before joining IDEMIA, Mr. Barreau worked for SICPA SA, a growing Swiss company providing security features and systems as well as secured identification and authentication solutions and services, mostly to Governmental organizations. Mr. Barreau started in the division Security Inks as Regional Director in Switzerland and then became its global Sales and Marketing Director, before being appointed as Managing Director of Security Inks and Solutions Division.

Mr. Barreau has more than 25 years of experience in Finance, Sales, Marketing and General Management and occupied leading positions in international companies based in various countries, notably in Asia and Europe.

Mr. Barreau’s deep understanding of public markets, as well as his experience in managing a technologically driven company, will be essential in managing the joint growth of the Citizen Identity and Public Security business units of IDEMIA.

Additional Information about Ed Casey

Before joining IDEMIA, Mr. Casey spent 13 years within Serco Group plc, a leading provider of public services in defense, transport, immigration, healthcare and other citizen services. He held various senior management positions at Serco, including Group Chief Operating Officer and Member of the Board of Directors, Acting Group Chief Executive Officer, and Chief Executive Officer of Serco's Americas Division. Under Mr. Casey's leadership, the Americas business tripled in size and successfully integrated two acquisitions: RCI and SI International.

Prior to Serco, Mr. Casey held senior management positions in the energy, investment banking and private equity fields at NP Energy Inc., an energy marketing business he founded and later sold; Tenneco Energy; LG&E Energy Corp.; The Blackstone Group; and Fremont Group LLC.

Mr. Casey’s experience in IT value added services and in the public sector will be instrumental in supporting IDEMIA’s government clients in the USA and Canada in their digital transformation.

About IDEMIA

OT-Morpho is now IDEMIA, the global leader in Augmented Identity for an increasingly digital world, with the ambition to empower citizens and consumers alike to interact, pay, connect, travel and vote in ways that are now possible in a connected environment.

Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, we reinvent the way we think, produce, use and protect this asset, whether for individuals or for objects. We ensure privacy and trust as well as guarantee secure, authenticated and verifiable transactions for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.

With close to $3 billion in revenues, IDEMIA is the result of the coming together of OT (Oberthur Technologies) and Safran Identity & Security (Morpho). With 14,000 employees around the world of more than 80 nationalities, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter

Contact information

IDEMIA
Media:
Hanna Sebbah, +33 (0)6 63 73 30 30
hanna.sebbah@havas.com
or
Manon Gaudefroy, 33 (0)6 85 30 60 02
manon.gaudefroy@havas.com
or
Alisa Gribe-Marquis, T+33 (0)6 03 12 93 13
alisa.gribe-marquis@havas.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Beko Becomes the Naming Partner of Fenerbahçe Men's Basketball Team19.12.2018 13:00Tiedote

To forge its support to sports and healthy living, Beko is now the naming partner of Fenerbahçe Men's Basketball Team. Beko has been supporting basketball teams in Turkish Basketball League and also sponsored the European Basketball Championship for many years and now it takes on the naming partnership of Fenerbahçe Men's Basketball Team for 2.5 years. This new naming partnership agreement focuses on “Eat Like A Pro” – an initiative launched by Beko to fight childhood obesity. Through this collaboration, Beko plans to expand the scope of the campaign to promote healthy eating habits among children by advertising their hero basketball players as role models. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181219005026/en/ Beko Becomes Naming Partner of Fenerbahce Men’s Basketball Team (Photo: Business Wire) Beko, a leading white goods brand providing products and services in more than 130 countries, returns to investing in bas

Mopria Powers IPP Print Solution in Windows 10 Update19.12.2018 11:00Tiedote

The Mopria® Alliance, a global non-profit membership organization providing universal standards and solutions for print and scan, today announced that Microsoft, a member of the Mopria Alliance, has implemented an IPP printing solution based on the Mopria standard, in the latest version of the Windows 10 operating system. Mopria is a set of standards offering simple and seamless printing to millions of certified printers and multi-function printers. Beginning with Windows 10 October 2018 Update, Windows added support for Mopria certified printers. When users install a new printer and Windows Update is not available, Windows will automatically install the Mopria certified printers. This eliminates the need for users to install any additional software or drivers, allowing them to print easily, regardless of the printer’s brand. “Implementing the Mopria standard in the most recent Windows Update enables us to continue to modernize the printing process for our customers,” said David Lemson

Chugai's Satralizumab Receives FDA Breakthrough Therapy Designation for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders19.12.2018 11:00Tiedote

Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Chugai’s anti-interleukin-6 (IL-6) receptor humanized recycling antibody satralizumab, an investigational medicine for neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NMOSD). “Satralizumab is a recycling antibody created utilizing Chugai’s proprietary antibody engineering technologies. We are delighted by the FDA’s designation for this innovative antibody based on the results of a Chugai-initiated global Phase III study” said Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit, Dr. Yasushi Ito. “Satralizumab is designed to inhibit signaling of the inflammatory cytokine IL-6, which is known to play a role in the pathogenesis of NMO/NMOSD. We continue our efforts to hopefully bring satralizumab as a new treatment option as soon as possible to people living with this devastating disease

Chugai’s Satralizumab Meets Primary Endpoint in Phase III Monotherapy Study in NMOSD19.12.2018 11:00Tiedote

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that a phase III monotherapy study of satralizumab (development code: SA237), SAkuraStar Study (NCT02073279) for the treatment of neuromyelitis optica spectrum disorder (NMOSD), which currently has no approved treatments, has achieved the primary endpoint. The primary endpoint was time to first protocol-defined relapse in the double-blind period. A statistically significant reduction in the risk of relapse was confirmed in patients who received satralizumab, compared to those who received placebo. Furthermore, the safety profile of satralizumab was consistent with that seen in previous studies. Further details will be presented at a future medical meeting. “We are pleased that satralizumab showed benefits also in a monotherapy setting following the previous results as add-on to baseline treatment in patients with NMOSD,” said Dr. Yasushi Ito, Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit. “We wil

SES Successfully Placed EUR 400 Million Multi-Tranche Schuldschein Loan19.12.2018 10:50Tiedote

SES S.A., the world’s leading satellite operator, has completed the syndication of Schuldschein Loans for a total amount of EUR 400 million, comprising a EUR 150 million 5.5-year floating tranche at Euribor 6 months plus 0.80% and a EUR 250 million 7-year fixed rate tranche with a coupon of 1.71%. SES is rated Baa2/BBB- (both with stable outlook). The Schuldschein loan was upsized from the initially marketed size and was placed with several European and Asian institutions. The proceeds will support SES’ general corporate purposes and the refinancing of existing debt maturities which include a USD 500 million 144A bond with a coupon of 2.5% and a final maturity date of 25 March 2019. Andrew Browne, Chief Financial Officer of SES, commented: “We are pleased to have secured this financing at very attractive terms and expanding our investor base while extending our debt maturity profile, where we now have no further senior debt maturities to be financed until early 2020.” BNP Paribas, ING

Bentall Kennedy and GreenOak Real Estate Announce Merger to Form Bentall GreenOak, Global Real Estate Investment Platform19.12.2018 10:39Tiedote

Bentall Kennedy and GreenOak Real Estate (“GreenOak”) announced today the signing of an agreement to merge the two firms into a leading global real estate investment platform. The combined entity will be named Bentall GreenOak. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181218005992/en/ GreenOak Co-Founders, John Carrafiell and Sonny Kalsi, existing GreenOak senior management and GreenOak’s strategic partner Tetragon Financial Group Limited will all continue to hold significant ownership stakes in Bentall GreenOak. Bentall Kennedy’s senior management team will also acquire a meaningful ownership position in the combined firm. Bentall GreenOak will be majority-owned by Sun Life Financial (“Sun Life”) and will operate under Sun Life Investment Management, the alternative asset management arm of Sun Life. Sun Life has committed significant co-investment capital to support the growth of Bentall GreenOak and to enhance the fi

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme